Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options.
OBJECTIVE
To address the therapeutic efficacy of various treatment regimens in genotype 3 selecting randomized clinical trials and prospective National Cohort Studies.


METHODS
(1) PEG-INF-based therapy including sofosbuvir (SOF) + RBV for 12 wk vs SOF + RBV 24 wk; (2) SOF + RBV therapy 12 wk/16 wk vs 24 wk; and (3) the role of RBV in SOF + daclatasvir (DCV) and SOF + ledipasvir (LDV) combinations. This meta-analysis provides robust information with the intention of addressing treatment strategy for hepatitis C virus genotype 3.


RESULTS
A combination treatment including SOF + RBV + PEG-IFN for 12 wk notes better SVR than with only SOF + RBV for 12 wk, although its association with more frequent adverse effects may be a limiting factor. Longer duration therapy with SOF + RBV (24 wk) has achieved higher SVR rates than shorter durations (12 or 16 wk). SOF + LDV are not an ideal treatment for genotype 3.


CONCLUSIONS
Lastly, SOF + DCV combination is probably the best oral therapy option and the addition of RBV does not appear to be needed to increase SVR rates substantially.
Javier Ampuero, Manuel Romero-Gomez, Inter-Centre Unit of Digestive Diseases and CIBERehd, Virgen Macarena, Virgen del Rocío University Hospitals, University of Sevilla, 41018 Sevilla, Spain.
Javier
J
Ampuero
Javier Ampuero, Manuel Romero-Gomez, Inter-Centre Unit of Digestive Diseases and CIBERehd, Virgen Macarena, Virgen del Rocío University Hospitals, University of Sevilla, 41018 Sevilla, Spain.
K Rajender
KR
Reddy
Javier Ampuero, Manuel Romero-Gomez, Inter-Centre Unit of Digestive Diseases and CIBERehd, Virgen Macarena, Virgen del Rocío University Hospitals, University of Sevilla, 41018 Sevilla, Spain.
Manuel
M
Romero-Gomez
D000284:Administration, Oral; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002219:Carbamates; D024882:Drug Resistance, Viral / Q000235:genetics; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics* / Q000472:pathogenicity; D006526:Hepatitis C / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D016017:Odds Ratio; D011446:Prospective Studies; D011759:Pyrrolidines; D016032:Randomized Controlled Trials as Topic; D012254:Ribavirin / Q000627:therapeutic use; D000069474:Sofosbuvir / Q000627:therapeutic use; D000072230:Sustained Virologic Response; D013997:Time Factors; D014633:Valine / Q000031:analogs & derivatives
D000998:Antiviral Agents; D002219:Carbamates; D007093:Imidazoles; D011759:Pyrrolidines; D012254:Ribavirin; D014633:Valine; C549273:daclatasvir; D000069474:Sofosbuvir
Daclatasvir; Genotype 3; Hepatitis C; Ledipasvir; Sofosbuvir